FY2024 Earnings Estimate for ATRA Issued By HC Wainwright
HC Wainwright issued their FY2024 EPS estimates for Atara Biotherapeutics in a research note issued to investors on Wednesday, January 22nd. HC Wainwright analyst R. Burns forecasts that the ...
HC Wainwright Reiterates “Neutral” Rating for Atara Biotherapeutics (NASDAQ:ATRA)
Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report)‘s stock had its “neutral” rating reiterated by analysts at HC ...
BioSpace3d
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...
Atara Biotherapeutics Faces Strategic Uncertainty Amid FDA Hold and CRL Issues
H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence: ...
BioPharma Dive3d
Intellia makes progress on HAE study; 2 more China drug deals
The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment. Elsewhere, the FDA imposed a hold on Atara and lifted another on Amylyx.
Stifel cuts Atara Biotherapeutics target to $5, holds rating
Stifel analysts adjusted their outlook on Atara Biotherapeutics (NASDAQ:ATRA) stock, reducing the price target to $5 from the previous $10, while maintaining a Hold rating on the shares. The decision ...
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs
On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...
Atara Biotherapeutics Faces Uncertainty Amid FDA Clinical Hold and Financing Needs, Resulting in Hold Rating
Atara Biotherapeutics (ATRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Benjamin ...
US FDA puts clinical hold on Atara's trials for cancer cell therapies
Atara Biotherapeutics said on Tuesday the U.S. health regulator has placed a clinical hold on its trials for cancer cell therapies, sending the drug developer's shares down more than 4% in premarket ...
precisionmedicineonline4d
Atara Biotherapeutics Receives FDA Complete Response Letter for Ebvallo
The FDA didn't approve the therapy in EBV-positive post-transplant lymphoproliferative disease due to findings at a third-party manufacturing facility.
FiercePharma4d
Atara's Ebvallo and pipeline candidate put on clinical hold in US after partner's failed plant inspection
After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...
Atara's New Drug Applications Placed on Hold by FDA
Atara Biotherapeutics said the U.S. Food and Drug Administration placed a clinical hold on its active investigational new drug applications. The biotechnology company said the FDA put a hold on its ...